<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Horwitz, Mara J.</style></author><author><style face="normal" font="default" size="100%">Brown, Jacques P.</style></author><author><style face="normal" font="default" size="100%">McClung, Michael R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Novel Approaches to the Treatment of Osteoporosis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-18 15:35:55</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-22</style></pages><abstract><style  face="normal" font="default" size="100%">The 2 currently available categories of osteoporosis therapies are the antiresorptive agents, which decrease bone resorption and bone formation, and parathyroid hormone agonists, which increase bone formation and bone resorption. Cathepsin K inhibition is a new mechanism of action that inhibits bone resorption while preserving bone formation.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>